Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Since the advent of biologic therapy for psoriasis in 2003, continued development of cytokine antagonists has yielded progressively better clinical outcomes, as assessed using the Psoriasis Area and Severity Index (PASI) or Patient's Global Assessment. In addition, more targeted therapies seemingly afford better patient adherence.
During submission, an incorrect Fig 5 showing heat map results instead of immunohistochemistry results was erroneously inserted. Please view the correct Fig 5 here. Representative images of ADAM23 and GPRIN1 localization in normal acral skin, psoriasis vulgaris and PPPP as shown by immunohistochemistry. There is an increase in expression of ADAM23 and GPRIN1 in PPPP as compared to psoriasis vulgaris and normal acral skin.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
